［1］Yamaguchi M，Suzuki R，Oguchi M，et al.Treatments and outcomes of patients with extranodal natural killer/T-cell lymphoma diagnosed between 2000 and 2013：A cooperative study in Japan［J］.Journal of Clinical Oncology，2017，35(1)：32.
[2]Rai MP，Bedi PS，Marinas EB，et al.Angioimmunoblastic T-cell lymphoma：A rare subtype of peripheral T-cell lymphoma［J］.Clinical Case Reports，2018，6(4)：750.
[3]KANG SY，SUN JL，TAO YX，et al.Clinical characteristics and a prognosis of vascular immunoblastic T cell lymphoma：A report of 25 cases［J］.Journal of Difficult Diseases，2013，12(7)：513-516.［康愫意，孙剑笠，陶云霞，等.血管免疫母细胞性 T 细胞淋巴瘤25 例临床特征及预后分析［J］.疑难病杂志，2013，12(7)：513-516.］
[4]Sidorova YV，Chernova NG，Yakutik IA，et al.Quantitative RHOA Gly17Val allele-specific polymerase chain reaction and T-cell clonality analysis in angioimmunoblastic T-cell lymphoma［J］.2018，12(4)：41-49.
[5]Kameoka Y，Takahashi N，Itou Stil，et al.Analysis of clinical characteristics and prognostic factors for angioimmunoblastic T-cell lymphoma［J］.Int J Hematol，2015，101(6)：536-542.
[6]Vallois D，Dobay MP，Morin RD，et al.Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas［J］.Blood，2017，128(11)：1490-1502.
[7]Federico M，Rudiger T，Bellei M，et al.Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma：Analysis of the international peripheral T-cell lymphoma project［J］.Journal of Clinical Oncology，2013，31(2)：240-246.
[8]Feldman AL，Law M，Remstein ED，et al.Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas［J］.Leukemia，2009（23）：574-580.
[9]Bisig B，de Reynies A，Bonnet C，et al.CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features［J］.Haematologica，2013（98）：1250-1258.
[10]Mi HH，Park HY，Ko YH，et al.IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma［J］.Journal of Cancer，2017，8(6)：1018-1024.
[11]Lopez-Girona A，Heintel D，Zhang LH，et al.Lenalidomide downregulates the cell survival factor，interferon regulatory factor-4，providing a potential mechanistic link for predicting response［J］.British Journal of Haematology，2011，154(3)：325-336.
[12]Lu G，Middleton RE，Sun H，et al.The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins［J］.Science，2014(343)：305-309.
[13]Zinzani PL，Pellegrini C，Broccoli A，et al.Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified［J］.Leuk Lymphoma，2011(52)：1585-1588.
[14]Ham JS，Park HY，Ryu KJ，et al.Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma.［J］.Oncotarget，2017,30(2)：140-146.
[15]Tse E，Kwong YL.T-cell lymphoma：Microenvironment-related biomarkers［J］.Semin Cancer Biol，2015（34）：46-51.
[16]Howell JA，Khan SA，Knapp S，et al.The clinical role of circu-DNA in gastrointestinal malignancy［J］.Transl Res，2017（183）：137-154.
[17]Tard C，Rouxel O，Lehuen A.Regulatory role of natural killer T cells in diabetes［J］.Biomed J，2016，38(6)：484-495.
[18]Jankovic N，Geelen A，Winkels RM，et al.Adherence to the WCRF/AICR dietary recommendations for cancer prevention and risk of cancer in elderly from europe and the united states：A Meta-analysis within the CHANCES project［J］.Cancer Epidemiol Biomarkers Prev，2017，26(1)：136.
[19]Yong Ed.Cancer biomarkers：Written in blood［J］.Nature，2014，511(7511)：524-526.
[20]Palomero T，Couronné L，Khiabanian H，et al.Recurrent mutations in epigenetic regulators，RHOA and FYN kinase in peripheral T cell lymphomas［J］.Nature Genetics，2014，46(2)：166.
[21]Sakata-Yanagimoto M，Nakamoto-Matsubara R，Komori D，et al.Detection of the circulating tumor DNAs in angioimmunoblastic T-cell lymphoma［J］.Annals of Hematology，2017，96(9)：1471-1475.
[22]Camus V，Stamatoullas A，Mareschal S，et al.Detection and prognostic value of recurrent XPO1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin Lymphoma［J］.Haematologica，2016，101(9)：1094.
[23]Shah S，Wood K，Labadie B，et al.Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer［J］.Oncotarget，2018，9(4)：4375-4384.
[24]Kim TK，Park CS，Jang J，et al.Inhibition of VEGF-dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC14a［J］.Molecular Oncology，2018，12(3):356-372.
[25]Lee WJ，Kim YJ，Lee YJ，et al.Vascular endothelial growth factor protein expression is associated with a poor prognosis in patients with cutaneous extranodal natural killer/T-cell lymphoma［J］.British Journal of Dermatology，2018，178(1):e11-e12.
[26]Grace SA，Meeks MW，Chen Y，et al.Adipose triglyceride lipase(ATGL)expression is associated with adiposity and tumor stromal proliferation in patients with pancreatic ductal adenocarcinoma［J］.Anticancer Research，2017，37(2)：699.
[27]Yoon KA，Kim MK，Eom HS，et al.Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma［J］.Leukemia & Lymphoma，2017，58(11)：1.
[28]Zhang Q，Cao J，Xue K，et al.Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma［J］.Oncotargets & Therapy，2017(10)：145-151.
[29]Shen Y，Wu B，Wang X，et al.Health state utilities in patients with advanced non-small-cell lung cancer in China［J］.J Comp Eff Res，2018，7(5)：443-452.
[30]Li T，Liu X，Shen Q，et al.Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis［J］.Oncotarget，2016，7(18)：26580-26592.